New combo therapy takes on deadly brain cancer
NCT ID NCT06157541
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This trial tests a combination of donor immune cells (targeting a common virus) and the drug pembrolizumab (Keytruda) in 58 people with glioblastoma, an aggressive brain cancer. The goal is to see if this approach can shrink tumors and help patients live longer. The study has two parts: first finding the safest dose, then checking how well it works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Donor immune cells (CMV-specific T cells) and pembrolizumab (Keytruda)
What this could lead to
If it works, this could offer a new treatment option for glioblastoma, a tough brain cancer, by helping the immune system attack tumors more effectively.
What could go wrong
This is an early-phase trial with only 58 participants, so results may not apply broadly. There are risks of side effects from the immune cells and pembrolizumab, and the combination may not work as hoped.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA MULTIFORME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Austin Hospital
Heidelberg, Victoria, 3084, Australia
-
Newro Foundation
Bowen Hills, Queensland, 4006, Australia
-
Princess Alexandra Hospital
Woolloongabba, Queensland, 4102, Australia
-
Royal Brisbane and Women's Hospital
Herston, Queensland, 4006, Australia